PBAC's latest decision on Pneumococcal conjugate vaccine 13-valent (13vpcv) and pneumococcal polysaccharide vaccine 23-valent (23vppv): Recommended (2019). Considered for Prevention of pneumococcal disease in high-risk populations across the lifespan, including healthy adults aged ≥70 years (non-Aboriginal and Torres Strait Islander), Aboriginal and Torres Strait Islander adults aged ≥50 years, persons ≥5 years with high-risk medical conditions, and children under 5 years at very high risk of pneumococcal disease.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
High-risk populations including: healthy non-Aboriginal and Torres Strait Islander adults ≥70 years; Aboriginal and Torres Strait Islander adults ≥50 years; all persons ≥5 years newly diagnosed with conditions associated with very high risk of pneumococcal disease; non-Aboriginal and Torres Strait Islander children 2-12 months with very high risk; Aboriginal and Torres Strait Islander children <5 years in high-incidence areas (WA, QLD, SA, NT); and children 12-59 months with high-risk medical conditions.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
no vaccine
Economic model
CUA
ICER note
Cost-effectiveness review was conducted but specific ICER values are not stated in the PSD. The document references a CER report and discusses cost-effectiveness qualitatively (e.g., 'acceptable cost-effectiveness', 'high but acceptable cost-effectiveness') without publishing numeric ICER values.